MedRx Co., Ltd
4586.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.44B
Close$
Share Statistics
| Market cap | $3.44 Billion |
|---|---|
| Enterprise Value | $2.30 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-17.44 |
| Beta | 0.6 |
| Outstanding Shares | 59,594,214 |
Return
| Return on Equity | -53.93% |
|---|---|
| Return on Assets | -49.30% |
| Return on Invested Capital | -53.28% |
Valuation & Multiples
| P/E Ratio | -4.08 |
|---|---|
| PEG | -7.28 |
| Price to Sales | 29.0 |
| Price to Book Ratio | 2.23 |
| Enterprise Value to Revenue | 19.01 |
| Enterprise Value to EBIT | -2.62 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 7, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About MedRx Co., Ltd
21 employees
CEO: Yonehiro Matsumura Established in 2002 and headquartered in Higashikagawa, Japan, MedRx Co., Ltd is a pharmaceutical firm focused on developing drug formulations. The company primarily provides pharmaceutical products in Japan that leverage transdermal abs...